Screened 2026-09-10 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Immunovant, Inc. holds its Markdown at $38.10. Elevated stress, defensive posture warranted, held for 3 days.
As held on the ledger · 2026-09-10
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 3 days
Price at the screen
$38.10
Valuation
N/A trailing · -13.85 forward price to earnings
Values screen
PASS
Beta
0.81
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.00%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
18.42%
Below 33%
Cash held in interest-bearing accounts and securities is 18.4% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 27% discount to our $48.50 fair value.
Fair value range in USD, drawn from the 2026-09-10 screen. The gold marker is the market price at the same screen. A 27.3% margin of safety to the base estimate.
Third-party analyst targets: 16 covering, consensus None. The average target sits +27% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-10 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech Dreams Without Earnings Rarely Deliver
Picture a lab racing to prove one drug works while every quarter the cash pile shrinks. Immunovant sits in exactly that spot, posting zero profit margins and a minus 65 percent return on equity. The forward price to earnings ratio sits at minus 19.7 times, which tells you the business is still losing money at scale.
We pass despite the 16 analysts who rate it a buy and set a median target at our own fair value of 47 dollars. The gap between current price and that level looks attractive on paper, yet the complete absence of profits and deeply negative returns on capital make the setup too fragile for us. Ethical screens clear the name, but the numbers do not.
Risk sits in the usual biotech trap of clinical setbacks and repeated cash raises that dilute holders. Even a single late-stage failure can wipe out years of progress and send the shares far below any model. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IMVT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 12.2% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 46% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 86%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (17 analysts) rates it buy, with a mean price target of $44.
2026-08-02Markup$38.62+24.1%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 24.1% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 46% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 86%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (17 analysts) rates it buy, with a mean price target of $44.
2026-07-18Markup$31.11+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 46% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 86%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (17 analysts) rates it buy, with a mean price target of $44.
2026-07-03Markup$31.11+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$31.11Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
